Emmaus Life Sciences, Inc. (EMMA): Net Income
-$7.49M
Year ended 2025-12-31
-$6.02M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$7.49M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$6.45M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$3.73M | n/m | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | -$10.62M | n/m | 2024-07-03, From 2022-01-01 |
| 2021-12-31 | -$15.95M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $1.35M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$54.84M | n/m | 2021-08-10, From 2019-01-01 |
| 2018-12-31 | -$72.59M | n/a | 2021-01-25, From 2018-01-01 |
| No annual figure between 2017-09-30 and 2018-12-31. | |||
| 2017-09-30 | -$7.11M | n/m | 2018-12-11, From 2016-10-01 |
| 2016-09-30 | -$5.94M | n/m | 2017-12-29, From 2015-10-01 |
| 2015-09-30 | -$3.38M | n/m | 2016-12-22, From 2014-10-01 |
| 2014-09-30 | -$2.66M | n/m | 2016-01-05, From 2013-10-01 |
| 2013-09-30 | -$10.91M | n/m | 2014-12-29, From 2012-10-01 |
| 2012-09-30 | -$3.41M | n/m | 2013-12-23, From 2011-10-01 |
| 2011-09-30 | -$8.87M | n/m | 2013-01-15, From 2010-10-01 |
| 2010-09-30 | -$8.17M | n/a | 2011-12-22, From 2009-10-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$7.49M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$99.50M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$68.87M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$124.02M | n/m |
| Palatin Technologies Inc (PTN) | 2026-06-30 | -$8.38M | n/m |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$53.58M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$958.0K | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$79.62M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$33.50M | n/m |
Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗